212 related articles for article (PubMed ID: 21430488)
41. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
42. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
43. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
[TBL] [Abstract][Full Text] [Related]
44. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
György B; Robert K; László C; Andrea J;
Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
[TBL] [Abstract][Full Text] [Related]
45. Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: a multicenter study.
Jung WY; Kim SG; Lee JS; Kang DH; Jung BJ; Shin DH; Lee YM; Choi SH
Psychiatry Clin Neurosci; 2015 Jan; 69(1):43-8. PubMed ID: 24902868
[TBL] [Abstract][Full Text] [Related]
46. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
47. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
Ou JJ; Xu Y; Chen HH; Fan X; Gao K; Wang J; Guo XF; Wu RR; Zhao JP
Psychopharmacology (Berl); 2013 Feb; 225(3):627-35. PubMed ID: 22926006
[TBL] [Abstract][Full Text] [Related]
48. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
[TBL] [Abstract][Full Text] [Related]
50. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
[TBL] [Abstract][Full Text] [Related]
51. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
[TBL] [Abstract][Full Text] [Related]
52. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
[TBL] [Abstract][Full Text] [Related]
53. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
54. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
[TBL] [Abstract][Full Text] [Related]
55. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
Pappadopulos E; Newcomer JW; Kolluri S
J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
57. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
[TBL] [Abstract][Full Text] [Related]
60. Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
Stewart M; DelBello MP; Versavel M; Keller D
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):635-40. PubMed ID: 20035581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
